Botulinum toxin injections for paediatric incontinence.

Details

Serval ID
serval:BIB_4E50F0299ECC
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Title
Botulinum toxin injections for paediatric incontinence.
Journal
Current Opinion in Urology
Author(s)
Schurch B., Corcos J.
ISSN
0963-0643 (Print)
ISSN-L
0963-0643
Publication state
Published
Issued date
2005
Volume
15
Number
4
Pages
264-267
Language
english
Notes
Publication types: Journal Article ; ReviewPublication Status: ppublish
Abstract
PURPOSE OF REVIEW: This review highlights a recent innovation in the medical treatment of children with neurogenic detrusor overactivity. Anticholinergics are usually the main way to treat bladder overactivity. Side effects and lack of efficacy are the two main causes for considering alternative treatment. Up to recently, invasive surgery, mainly bladder augmentation, was the only available treatment for these intractable bladders. Here, we report on botulinum A toxin injection as an alternative to surgery in children with neurogenic detrusor overactivity.
RECENT FINDINGS: There are only four published articles on the use of botulinum A toxin in children with neurogenic detrusor overactivity. However, an increasing number of reports indicate clinical benefit and a good safety profile of botulinum A toxin in neurogenic and idiopathic detrusor overactivity. Extrapolation of the data published in adults treated with botulinum A toxin injections and understanding the mechanism of action on the detrusor muscle are worthwhile to encourage paediatric physicians to propose this option to their patients. Furthermore, the literature does not seem to warn against drug resistance or ultrastructural changes of the detrusor after repeated injection.
SUMMARY: Botulinum A toxin appears to be a reasonable alternative to surgery in the management of intractable overactive bladder in children. However, studies of the delivery method, site of injection, dose and long-term follow-up are required to confirm the good safety profile/clinical benefit of this new, minimally invasive approach.
Keywords
Animals, Botulinum Toxins, Type A/pharmacology, Botulinum Toxins, Type A/therapeutic use, Child, Humans, Injections, Neuromuscular Agents/pharmacology, Neuromuscular Agents/therapeutic use, Urinary Bladder, Neurogenic/drug therapy, Urinary Incontinence/drug therapy
Pubmed
Web of science
Create date
05/11/2014 12:12
Last modification date
20/08/2019 14:03
Usage data